TokenPost·
Geron Plans to Discontinue Late-Stage Rytelo Trial After Efficacy Concerns
Geron shares fell more than 20% Wednesday as the company moved to end the study.
More news
- TokenPostCVNA Rises 11% in One Hour, Outpacing Its 24-Hour Gain
- Crypto BriefingApple reportedly agreed $1B annual deal with Google for Gemini technology access
- TokenPostBristol-Myers Squibb Q3 Estimates Show Revenue Up, EPS Down
- TokenPostKatana Inu Sets Steam Early Access for Oct. 22 as PS5 Plans Diverge
- crypto.newsXRP Ledger adds Flare to validator list as Anodos steps down
- NewsBTCEthereum Developers Delay Glamsterdam Hoodi Upgrade Without New Date